Rhumbline Advisers Invests $244,000 in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP)

Rhumbline Advisers purchased a new position in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 13,670 shares of the company's stock, valued at approximately $244,000. Rhumbline Advisers owned 0.21% of Tonix Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Commonwealth Equity Services LLC acquired a new stake in shares of Tonix Pharmaceuticals in the fourth quarter valued at $40,000. Two Sigma Investments LP acquired a new stake in Tonix Pharmaceuticals in the fourth quarter valued at $66,000. Northern Trust Corp acquired a new stake in shares of Tonix Pharmaceuticals during the fourth quarter worth about $162,000. Point72 Asset Management L.P. purchased a new position in shares of Tonix Pharmaceuticals during the fourth quarter worth about $526,000. Finally, Jane Street Group LLC grew its holdings in shares of Tonix Pharmaceuticals by 5,932.3% during the fourth quarter. Jane Street Group LLC now owns 1,662,682 shares of the company's stock worth $548,000 after buying an additional 1,635,119 shares during the last quarter. 82.26% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Seth Lederman acquired 4,000 shares of the firm's stock in a transaction that occurred on Thursday, May 15th. The stock was purchased at an average price of $21.55 per share, with a total value of $86,200.00. Following the purchase, the chief executive officer now owns 4,005 shares of the company's stock, valued at approximately $86,307.75. This trade represents a 80,000.00% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. 0.03% of the stock is currently owned by insiders.

Tonix Pharmaceuticals Trading Up 8.8%

Shares of NASDAQ:TNXP opened at $35.67 on Wednesday. The firm's 50 day moving average is $27.44 and its two-hundred day moving average is $24.41. The firm has a market capitalization of $262.53 million, a P/E ratio of -0.02 and a beta of 2.09. Tonix Pharmaceuticals Holding Corp. has a 52 week low of $6.76 and a 52 week high of $130.00.

Tonix Pharmaceuticals (NASDAQ:TNXP - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The company reported ($2.84) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.23) by $0.39. The business had revenue of $2.43 million during the quarter, compared to analysts' expectations of $2.55 million. Tonix Pharmaceuticals had a negative net margin of 1,313.87% and a negative return on equity of 120.96%. Analysts predict that Tonix Pharmaceuticals Holding Corp. will post -1762.5 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on TNXP shares. Wall Street Zen upgraded shares of Tonix Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Alliance Global Partners reissued a "buy" rating on shares of Tonix Pharmaceuticals in a research report on Tuesday, June 3rd. Finally, Noble Financial reaffirmed an "outperform" rating and set a $70.00 price target on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th.

Tonix Pharmaceuticals Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.

Want to see what other hedge funds are holding TNXP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.